[CAS NO. 1422535-52-1] T-3775440 HCl

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1422535-52-1]

Catalog

SLK-S8438

Brand

Selleck

CAS

1422535-52-1

DESCRIPTION [1422535-52-1]

Overview

MDL	-
Molecular Weight	346.85
Molecular Formula	C18H23ClN4O
SMILES	O=C(C1=CN(C)N=C1)NC2=CC=C([C@H]3[C@H](NCC4CC4)C3)C=C2.[H]Cl

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.8831 mL	14.4155 mL	28.8309 mL
5 mM	0.5766 mL	2.8831 mL	5.7662 mL
10 mM	0.2883 mL	1.4415 mL	2.8831 mL
50 mM	0.0577 mL	0.2883 mL	0.5766 mL

Description

T-3775440 HCl is an irreversible inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.

Targets

LSD1 ^[1]

2.1 nM

In vitro

T-3775440 treatment enforces transdifferentiation of erythroid/megakaryocytic lineages into granulomonocytic-like lineage cells. T-3775440 disrupts the interaction between LSD1 and growth factor-independent 1B (GFI1B), a transcription factor critical for the differentiation processes of erythroid and megakaryocytic lineage cells. 48-hour T-3775440 treatment induces cell-cycle arrest and apoptosis in AEL (TF-1a, HEL92.1.7) and AMKL cell lines (CMK11-5, M07e). T-3775440 treatment increases the G1 and sub-G1 phase populations in TF-1a and CMK11-5 cells.

References

[1] Ishikawa Y, et al. Mol Cancer Ther. 2017, 16(2):273-284.
[2] Ishikawa Y, et al. Oncogenesis. 2017, 6(9):e377.